CLAIMS

1. A peptide ligand specific for the collagen binding site of MT1-MMP comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a non-aromatic molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises an amino acid sequence selected from:

C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1)

wherein C_i, C_{ii} and C_{iii} represent first, second and third cysteine residues, respectively or a pharmaceutically acceptable salt thereof.

2. The peptide ligand as defined in claim 1, wherein the peptide ligand of C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1) is selected from:

CPYSWETCLFGDYRC (SEQ ID NO: 2);
CPFDWHTCLFGDYTC (SEQ ID NO: 3);
CPFDWHTCLFGEYSC (SEQ ID NO: 4);
CPIDWHTCLFGDYTC (SEQ ID NO: 5);
CPFSWHTCLFGEYSC (SEQ ID NO: 6):
CPFSWHTCLFGDYTC (SEQ ID NO: 7);
CPISWHTCLFGDYSC (SEQ ID NO: 8); and
CPYSWHTCLFGDYSC (SEQ ID NO: 9).

3. The peptide ligand as defined in claim 2, wherein the peptide ligand of C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1) is further selected from:

A-(SEQ ID NO: 2)-A (BCY1026);
A-(SEQ ID NO: 3)-A (BCY1057);
A-(SEQ ID NO: 4)-A (BCY1065);
A-(SEQ ID NO: 5)-A (BCY1067);
A-(SEQ ID NO: 6)-A (BCY1073);
A-(SEQ ID NO: 7)-A (BCY1074);
A-(SEQ ID NO: 8)-A (BCY1075); and
A-(SEQ ID NO: 9)-A (BCY1076).

4. The peptide ligand as defined in claim 1 or claim 2, wherein the molecular scaffold is TATA.

5. The peptide ligand as defined in claim 4, wherein the molecular scaffold is TATA and the peptide ligand of C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1) is selected from:

A-(SEQ ID NO: 2)-A (BCY1026);
A-(SEQ ID NO: 3)-A (BCY1057);
A-(SEQ ID NO: 4)-A (BCY1065);
A-(SEQ ID NO: 5)-A (BCY1067);
A-(SEQ ID NO: 6)-A (BCY1073);
A-(SEQ ID NO: 7)-A (BCY1074);
A-(SEQ ID NO: 8)-A (BCY1075); and
A-(SEQ ID NO: 9)-A (BCY1076).

6. The peptide ligand as defined in any one of claims 1 to 5, wherein the pharmaceutically acceptable salt is selected from the free acid or the sodium, potassium, calcium, ammonium salt.

7. The peptide ligand as defined in any one of claims 1 to 6, wherein the MT1-MMP is human MT1-MMP.

8. A drug conjugate comprising a peptide ligand as defined in any one of claims 1 to 7, conjugated to one or more effector and/or functional groups.

9. The drug conjugate as defined in claim 8, conjugated to one or more cytotoxic agents.

10. The drug conjugate as defined in claim 9, wherein said cytotoxic agent is selected from MMAE or DM1.

11. A pharmaceutical composition which comprises the peptide ligand of any one of claims 1 to 6 or the drug conjugate of any one of claims 8 to 10, in combination with one or more pharmaceutically acceptable excipients.

12. The pharmaceutical composition as defined in claim 11, which additionally comprises one or more therapeutic agents.

13. The drug conjugate as defined in any one of claims 8 to 10, for use in a therapy for preventing, suppressing or treating a disease or disorder mediated by MT1-MMP.

14. Use of the drug conjugate as defined in any one of claims 8 to 10 in the manufacture of a medicament for preventing, suppressing or treating a disease or disorder mediated by MT1-MMP in a subject.

15. The use of drug conjugate as defined in claim 14, wherein the disease or disorder mediated by MT1-MMP includes cancers.

16. The use of drug conjugate as defined in claim 14, wherein the disease or disorder mediated by MT1-MMP includes non-small cell lung carcinomas.